Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Medicxi is a European venture capital firm established in 2016 by the former Index Ventures life sciences team. The firm manages the Index Ventures life sciences portfolio while currently investing from its latest fund, Medicxi IV. Notable investors include GlaxoSmithKline, Johnson & Johnson Innovation, Novartis, and Verily.
Medicxi invests in the life sciences sector, specifically targeting biotech companies throughout the drug development continuum. The firm focuses on early-stage innovation, particularly companies that have achieved clinical proof-of-concept and are preparing for pivotal studies and regulatory approvals. Investment stages range from pre-seed to Series C, with an emphasis on asset-centric financing.
Email investor@medicxi.com with your deck to pitch Medicxi.
Yes, Medicxi often leads investment rounds, particularly in early-stage biotech companies that have demonstrated clinical proof-of-concept.
Medicxi is open to follow-on investments, especially for companies that show significant progress in their drug development journey.
Medicxi is currently investing from its latest fund, Medicxi IV, although specific fund size details are not disclosed.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.